Castle Biosciences Study Finds DecisionDx-UM Plus PRAME Outperforms Gene Mutation Analysis in Uveal Melanoma Prognosis

Reuters12-17

<a href="https://laohu8.com/S/CSTL">Castle Biosciences</a> Study Finds DecisionDx-UM Plus PRAME Outperforms Gene Mutation Analysis in Uveal Melanoma Prognosis

Castle Biosciences Inc. announced new data from the largest prospective, multicenter study to date comparing next-generation sequencing $(NGS)$-based gene mutation analysis with the combination of DecisionDx-UM and PRAME gene expression for predicting outcomes in patients with uveal melanoma (UM). The study, titled "Early Genetic Evolution of Driver Mutations in Uveal Melanoma," was conducted by the Collaborative Ocular Oncology Group (COOG) and has been published in Nature Communications. Results showed that the combination of DecisionDx-UM and PRAME outperformed gene mutation analysis in predicting metastasis-free survival and overall survival in UM patients. The study authors attribute the improved performance to the ability of DecisionDx-UM to measure gene activity from both tumor and surrounding immune cells, providing a comprehensive assessment of the tumor microenvironment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9603172-en) on December 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592940009?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592940009","market":"nz","top_or_hot":-1,"title":"Castle Biosciences Study Finds DecisionDx-UM Plus PRAME Outperforms Gene Mutation Analysis in Uveal Melanoma Prognosis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CSTL\">Castle Biosciences</a> Study Finds DecisionDx-UM Plus PRAME Outperforms Gene Mutation Analysis in Uveal Melanoma Prognosis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Castle Biosciences Inc. announced new data from the largest prospective, multicenter study to date comparing next-generation sequencing <a href=\"https://laohu8.com/S/NGS\">$(NGS)$</a>-based gene mutation analysis with the combination of DecisionDx-UM and PRAME gene expression for predicting outcomes in patients with uveal melanoma (UM). The study, titled \"Early Genetic Evolution of Driver Mutations in Uveal Melanoma,\" was conducted by the Collaborative Ocular Oncology Group (COOG) and has been published in Nature Communications. Results showed that the combination of DecisionDx-UM and PRAME outperformed gene mutation analysis in predicting metastasis-free survival and overall survival in UM patients. The study authors attribute the improved performance to the ability of DecisionDx-UM to measure gene activity from both tumor and surrounding immune cells, providing a comprehensive assessment of the tumor microenvironment.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9603172-en) on December 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Castle Biosciences Study Finds DecisionDx-UM Plus PRAME Outperforms Gene Mutation Analysis in Uveal Melanoma Prognosis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCastle Biosciences Study Finds DecisionDx-UM Plus PRAME Outperforms Gene Mutation Analysis in Uveal Melanoma Prognosis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-17 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CSTL\">Castle Biosciences</a> Study Finds DecisionDx-UM Plus PRAME Outperforms Gene Mutation Analysis in Uveal Melanoma Prognosis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Castle Biosciences Inc. announced new data from the largest prospective, multicenter study to date comparing next-generation sequencing <a href=\"https://laohu8.com/S/NGS\">$(NGS)$</a>-based gene mutation analysis with the combination of DecisionDx-UM and PRAME gene expression for predicting outcomes in patients with uveal melanoma (UM). The study, titled \"Early Genetic Evolution of Driver Mutations in Uveal Melanoma,\" was conducted by the Collaborative Ocular Oncology Group (COOG) and has been published in Nature Communications. Results showed that the combination of DecisionDx-UM and PRAME outperformed gene mutation analysis in predicting metastasis-free survival and overall survival in UM patients. The study authors attribute the improved performance to the ability of DecisionDx-UM to measure gene activity from both tumor and surrounding immune cells, providing a comprehensive assessment of the tumor microenvironment.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9603172-en) on December 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4112","symbol_name":"金融交易所和数据","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL5qzbNT:1","article_id":"2592940009","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592940009","pubTimestamp":1765972814,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Castle Biosciences Inc. announced new data from the largest prospective, multicenter study to date comparing next-generation sequencing -based gene mutation analysis with the combination of DecisionDx-UM and PRAME gene expression for predicting outcomes in patients with uveal melanoma . The study, titled \"Early Genetic Evolution of Driver Mutations in Uveal Melanoma,\" was conducted by the Collaborative Ocular Oncology Group  and has been published in Nature Communications. Results showed that the combination of DecisionDx-UM and PRAME outperformed gene mutation analysis in predicting metastasis-free survival and overall survival in UM patients. The study authors attribute the improved performance to the ability of DecisionDx-UM to measure gene activity from both tumor and surrounding immune cells, providing a comprehensive assessment of the tumor microenvironment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4112":"金融交易所和数据","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","BK4585":"ETF&股票定投概念","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4196":"保健护理服务","CSTL":"Castle Biosciences, Inc.","BK4588":"碎股"},"translate_title":"Castle Biosciences研究发现DecisionDx-UM加PRAME在葡萄膜黑色素瘤预后方面优于基因突变分析","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"CSTL":0.9},"content_text":"Castle Biosciences Study Finds DecisionDx-UM Plus PRAME Outperforms Gene Mutation Analysis in Uveal Melanoma Prognosis\n    \n\n        Castle Biosciences Inc. announced new data from the largest prospective, multicenter study to date comparing next-generation sequencing $(NGS)$-based gene mutation analysis with the combination of DecisionDx-UM and PRAME gene expression for predicting outcomes in patients with uveal melanoma (UM). The study, titled \"Early Genetic Evolution of Driver Mutations in Uveal Melanoma,\" was conducted by the Collaborative Ocular Oncology Group (COOG) and has been published in Nature Communications. Results showed that the combination of DecisionDx-UM and PRAME outperformed gene mutation analysis in predicting metastasis-free survival and overall survival in UM patients. The study authors attribute the improved performance to the ability of DecisionDx-UM to measure gene activity from both tumor and surrounding immune cells, providing a comprehensive assessment of the tumor microenvironment.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9603172-en) on December 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592940009","isCrawlerRequest":true}